Dec 15 (Reuters) – Kyverna Therapeutics said on Monday its experimental cell therapy for treating patients with a rare movement disorder met the main goal of a mid-stage study, sending its shares surging 20% in premarket trading.
The therapy, KYV-101, was being tested in patients with stiff person syndrome, a rare autoimmune disorder that makes muscles rigid and causes painful spasms, often affecting the back and legs and making it hard to walk or move normally.
A single dose of KYV-101 significantly improved patients’ ability to walk and reduced muscle stiffness, while allowing them to stop other immune-suppressing drugs, the Emeryville-based company said. Most patients who needed walking aids before treatment no longer required them, it said.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar)
Comments